Manel Esteller: Bidirectional impact of epigenetics and genetics

Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, shared a post on X about his recent paper published in Cancer Discovery.

“Our Epigenetic Hallmarks of Cancer article in Cancer Discovery, AACR.

Bidirectional impact of epigenetics and genetics: DNA methylation, histone modifications and chromatin structure changes cause genomic aberrations; and mutations in DNMTs, histone modifiers and chromatin remodelers cause epigenome drifts: A ‘Yin and Yang’ model.”

“The Epigenetic Hallmarks of Cancer”

Authors: Manel Esteller, Mark Dawson, Cigall Kadoch, Feyruz Rassool, Peter Jones, Stephen Baylin.

More posts featuring Manel Esteller.

Manel Esteller is the Group Leader of Cancer Epigenetics at the Josep Carreras Institute and serves as the Chairman of Genetics at the University of Barcelona’s School of Medicine. He is also an ICREA Research Professor.

His current research focuses on mapping the epigenome and epitranscriptome of both normal and transformed cells, examining the interactions between epigenetic modifications and non-coding RNAs, and developing new epigenetic drugs for cancer therapy.

Previously, Dr. Esteller directed the Cancer Epigenetics and Biology Program (PEBC) in Barcelona and led the Josep Carreras Leukaemia Research Institute (IJC).